Patents by Inventor Christine Neuveut

Christine Neuveut has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Polynucleotides encoding MHC class I-restricted hTERT epitopes, analogues thereof or polyepitopes
    Patent number: 10767167
    Abstract: This invention relates to the field of anticancer therapy, and to the identification of immunogenic peptides derived from the human telomerase reverse transcriptase (hTERT). The present invention relates to polynucleotides encoding hTERT epitopes restricted to MHC class I molecule, analogues thereof and polyepitopes containing such epitopes and/or analogues. Are also included in the present invention, vector and cell comprising such polynucleotides. The present invention also concerns composition comprising hTERT polypeptides, corresponding polynucleotides, vectors and cells, for use in the treatment and/or prevention of cancer.
    Type: Grant
    Filed: April 6, 2017
    Date of Patent: September 8, 2020
    Assignees: INSTITUT PASTEUR, INSERM (INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE)
    Inventors: Pierre Langlade-Demoyen, Fransisco Garcia Pons, Olivier Adotevi, Sylvain Cardinaud, Christine Neuveut
  • POLYNUCLEOTIDES ENCODING MHC CLASS I-RESTRICTED HTERT EPITOPES, ANALOGUES THEREOF OR POLYEPITOPES
    Publication number: 20170298328
    Abstract: This invention relates to the field of anticancer therapy, and to the identification of immunogenic peptides derived from the human telomerase reverse transcriptase (hTERT). The present invention relates to polynucleotides encoding hTERT epitopes restricted to MHC class I molecule, analogues thereof and polyepitopes containing such epitopes and/or analogues. Are also included in the present invention, vector and cell comprising such polynucleotides. The present invention also concerns composition comprising hTERT polypeptides, corresponding polynucleotides, vectors and cells, for use in the treatment and/or prevention of cancer.
    Type: Application
    Filed: April 6, 2017
    Publication date: October 19, 2017
    Inventors: Pierre LANGLADE-DEMOYEN, Fransisco GARCIA PONS, Olivier ADOTEVI, Sylvain CARDINAUD, Christine NEUVEUT
  • Polynucleotides encoding MHC class I-restricted hTERT epitopes, analogues thereof or polyepitopes
    Patent number: 9624479
    Abstract: This invention relates to the field of anticancer therapy, and to the identification of immunogenic peptides derived from the human telomerase reverse transcriptase (hTERT). The present invention relates to polynucleotides encoding hTERT epitopes restricted to MHC class I molecule, analogs thereof and polyepitopes containing such epitopes and/or analogs. Are also included in the present invention, vector and cell comprising such polynucleotides. The present invention also concerns composition comprising hTERT polypeptides, corresponding polynucleotides, vectors and cells, for use in the treatment and/or prevention of cancer.
    Type: Grant
    Filed: August 26, 2013
    Date of Patent: April 18, 2017
    Assignees: INSTITUT PASTEUR, INSERM (INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE)
    Inventors: Pierre Langlade-Demoyen, Fransisco Garcia Pons, Olivier Adotevi, Sylvain Cardinaud, Christine Neuveut
  • Polynucleotides encoding MHC class I-restricted hTERT epitopes, analogues thereof or polyepitopes
    Patent number: 8858931
    Abstract: This invention relates to the field of anticancer therapy, and to the identification of immunogenic peptides derived from the human telomerase reverse transcriptase (hTERT). The present invention relates to polynucleotides encoding hTERT epitopes restricted to MHC class I molecule, analogs thereof and polyepitopes containing such epitopes and/or analogs. Are also included in the present invention, vector and cell comprising such polynucleotides. The present invention also concerns composition comprising hTERT polypeptides, corresponding polynucleotides, vectors and cells, for use in the treatment and/or prevention of cancer.
    Type: Grant
    Filed: July 31, 2006
    Date of Patent: October 14, 2014
    Assignees: Institut Pasteur, INSERM
    Inventors: Pierre Langlade-Demoyen, Fransisco Garcia Pons, Olivier Adotevi, Sylvain Cardinaud, Christine Neuveut
  • POLYNUCLEOTIDES ENCODING MHC CLASS I-RESTRICTED HTERT EPITOPES, ANALOGUES THEREOF OR POLYEPITOPES
    Publication number: 20140056932
    Abstract: This invention relates to the field of anticancer therapy, and to the identification of immunogenic peptides derived from the human telomerase reverse transcriptase (hTERT). The present invention relates to polynucleotides encoding hTERT epitopes restricted to MHC class I molecule, analogues thereof and polyepitopes containing such epitopes and/or analogues. Are also included in the present invention, vector and cell comprising such polynucleotides. The present invention also concerns composition comprising hTERT polypeptides, corresponding polynucleotides, vectors and cells, for use in the treatment and/or prevention of cancer.
    Type: Application
    Filed: August 26, 2013
    Publication date: February 27, 2014
    Applicants: INSERM (INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE), INSTITUT PASTEUR
    Inventors: Pierre LANGLADE-DEMOYEN, Fransisco GARCIA PONS, Olivier ADOTEVI, Sylvain CARDINAUD, Christine NEUVEUT
  • Polynucleotides encoding MHC class I-restricted hTERT epitopes, analogues thereof or polyepitopes
    Patent number: 8003773
    Abstract: This invention relates to the field of anticancer therapy, and to the identification of immunogenic peptides derived from the human telomerase reverse transcriptase (hTERT). The present invention relates to polynucleotides encoding hTERT epitopes restricted to MHC class I molecule, analogues thereof and polyepitopes containing such epitopes and/or analogues. Are also included in the present invention, vector and cell comprising such polynucleotides. The present invention also concerns composition comprising hTERT polypeptides, corresponding polynucleotides, vectors and cells, for use in the treatment and/or prevention of cancer.
    Type: Grant
    Filed: July 12, 2007
    Date of Patent: August 23, 2011
    Assignees: Institut Pasteur, INSERM
    Inventors: Pierre Langlade-Demoyen, Fransisco Garcia Pons, Olivier Adotevi, Sylvain Cardinaud, Christine Neuveut, Kostas Kosmatopoulos, Stéphanie Graff-Dubois, Jeanne Menez-Jamet
  • Polynucleotides encoding mhc class i-restricted htert epitopes, analogues thereof or polyepitopes
    Publication number: 20100172878
    Abstract: This invention relates to the field of anticancer therapy, and to the identification of immunogenic peptides derived from the human telomerase reverse transcriptase (hTERT). The present invention relates to polynucleotides encoding hTERT epitopes restricted to MHC class I molecule, analogues thereof and polyepitopes containing such epitopes and/or analogues. Are also included in the present invention, vector and cell comprising such polynucleotides. The present invention also concerns composition comprising hTERT polypeptides, corresponding polynucleotides, vectors and cells, for use in the treatment and/or prevention of cancer.
    Type: Application
    Filed: July 31, 2006
    Publication date: July 8, 2010
    Inventors: Pierre Langlade-Demoyen, Fransisco Garcia Pons, Olivier Adotevi, Sylvain Cardinaud, Christine Neuveut
  • Polynucleotides encoding MHC class I-restricted hTERT epitopes, analogues thereof or polyepitopes
    Publication number: 20090175892
    Abstract: This invention relates to the field of anticancer therapy, and to the identification of immunogenic peptides derived from the human telomerase reverse transcriptase (hTERT). The present invention relates to polynucleotides encoding hTERT epitopes restricted to MHC class I molecule, analogues thereof and polyepitopes containing such epitopes and/or analogues. Are also included in the present invention, vector and cell comprising such polynucleotides. The present invention also concerns composition comprising hTERT polypeptides, corresponding polynucleotides, vectors and cells, for use in the treatment and/or prevention of cancer.
    Type: Application
    Filed: July 12, 2007
    Publication date: July 9, 2009
    Applicants: INSTITUT PASTEUR, INSERM (INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE)
    Inventors: Pierre Langlade-Demoyen, Fransisco Garcia Pons, Olivier Adotevi, Syvain Cardinaud, Christine Neuveut, Kostas Kosmatopoulos, Stephanie Graff-Dubois, Jeanne Menez-Jamet